10-year survival after resection of pancreatic ductal adenocarcinoma with pathological re-examination of a nationwide cohort
Year: 2025
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Resection of pancreatic ductal adenocarcinoma (PDAC) is performed with curative intent, yet, long-term overall survival (OS) remains rare. This nationwide study assessed 10-year OS after resection of PDAC with diagnostic confirmation through pathological re-examination. METHODS: Patients were identified from the Netherlands Cancer Registry (NCR; 2000-2020). Kaplan-Meier survival analysis was performed to estimate the 10-year OS of the entire cohort, and for each of four consecutive 5-year periods to assess survival changes over time. Pathology data of patients who survived beyond 10 years was re-examined by two or more pancreatic pathologists. RESULTS: Among 5553 resected PDAC patients (2000-2020), estimated 10-year OS was 10.6 % with significant improvement across 5-year periods (P < 0.001). Actual 10-year OS after resection was reached by 179 patients (7.3 %). Review of available pathology reports (n = 173) revealed another diagnosis than PDAC (misregistration) in 21 patients (12.1 %). Of the remaining 152 patients, tissue could be retrieved for 108 patients (71.1 %), of whom 21 (19.4 %) had a different diagnosis after pathological re-examination (misclassification). Alternative diagnoses were benign (i.e., pancreatitis), premalignant (i.e., non-invasive IPMN), or other malignancies (i.e., distal cholangiocarcinoma, ampullary, duodenal, or acinar cell carcinoma). Of the 87 patients with confirmed PDAC, 12 patients (13.8 %) had a histological subtype other than conventional (classic) PDAC (e.g., adenosquamous or colloid carcinoma). After excluding the 42 misregistered or misclassified patients (24.3 %), the true observed 10-year OS after resection of PDAC was 5.3 %. CONCLUSION: The observed 10-year OS after resection of PDAC in a nationwide cohort was only 5.3 % after pathological re-examination.
Source: European Journal of Cancer
Institutions: Erasmus MC, Erasmus MC Cancer Institute, Netherlands Comprehensive Cancer Organisation, Amsterdam UMC Location University of Amsterdam, Cancer Center Amsterdam, Leiden University Medical Center, Catharina Ziekenhuis, Glasgow Royal Infirmary, University of Glasgow, University Medical Center Groningen, University of Groningen, Maastricht University Medical Centre, Maastricht University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,270
Funders: ZonMw, KWF Kankerbestrijding
OpenAlex ID: W4415950903
